Results 181 to 190 of about 599,334 (260)

Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

Addiction, EarlyView.
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper, Francesca Small, Sam Brown, Michael Kelleher, Luke Mitcheson, James Rucker, Allan H. Young, John Marsden   +7 more
wiley   +1 more source

Long-distance object motion evokes direction selectivity in retinal neurons through nicotinic receptors in bipolar cells. [PDF]

J Neurophysiol
Bohl JM, Garrett AM, Ichinose T.
europepmc   +1 more source

Examining the role of freebase nicotine in the harm reduction potential of oral nicotine pouches versus moist snuff: A randomized crossover trial

Addiction, EarlyView.
Abstract Background and aims Oral nicotine pouches (ONPs) contain varying proportions of freebase nicotine (FBN), with higher FBN expected to increase nicotine delivery across the oral mucosa. Because ONPs contain fewer toxicants than moist snuff and may serve as a reduced harm alternative for smokeless tobacco, we compared how the FBN in ONPs affects ...
Brittney Keller‐Hamilton, Hayley Curran, Leanne Atkinson, Sriya Suraapaneni, Alice Hinton, Kirsten Chrzan, Darren Mays, Ahmad El‐Hellani, Clark W. Wilson, Marielle C. Brinkman, Theodore L. Wagener   +10 more
wiley   +1 more source

Targeted Mutations Activate Allosteric Modulation of α5-Containing Nicotinic Acetylcholine Receptors. [PDF]

ACS Chem Neurosci
Marotta CB, Lester HA, Dougherty DA.
europepmc   +1 more source

Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study

Addiction, EarlyView.
Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin‐assisted psychotherapy for methamphetamine use disorder. Design Single arm, open label pilot study.
Elizabeth Knock, Krista J. Siefried, Gill Bedi, Steven Albert, Richard O. Day, Nadine Ezard, Margaret Ross, Paul Liknaitzky, Jonathan Brett   +8 more
wiley   +1 more source

Identification of α6-Containing Nicotinic Acetylcholine Receptors as the Primary Target of Nereistoxin Insecticides and Structural Basis of Channel Blockade. [PDF]

Insects
Gu L, Liang Y, Zhang B, Huang J, Qiao X.
europepmc   +1 more source

5‐Methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden, Michael Kelleher, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, Claire Roberts, James J. Rucker, Gemma Scott, Ivan Saeger, Francesca Small, Mathieu Seynaeve   +10 more
wiley   +1 more source

Outdated tools, underestimated harm: Modernizing cannabis surveillance in a post‐legalization era

Addiction, EarlyView.
Abstract Background Canada's 2018 legalization of non‐medical cannabis was positioned as a public health initiative, intended to shift cannabis use from criminalization to regulation. Since then, cannabis access and consumption have grown significantly but the systems used to monitor cannabis‐related harms have not kept pace.
Anees Bahji
wiley   +1 more source

The CAGE Framework (Calcium-Gated Excitability): From Single Neurotransmitters to Calcium States in the Tumor Microenvironment. [PDF]

Int J Mol Sci
Rudy LM, Godlewski MM.
europepmc   +1 more source

Varenicline for cannabis use disorder: A randomized controlled trial

Addiction, EarlyView.
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark, Kevin M. Gray, Nathaniel L. Baker, Brian J. Sherman, Bryan Tolliver, Jessica Burt, Alonzo Steplight, Elizabeth Chapman, Amanda Wagner   +8 more
wiley   +1 more source